Shinobi Therapeutics
Signal active
Organization
Contact Information
Overview
Shinobi Therapeutics is a biotechnology business that is working on a novel class of immune-evasive iPSC-derived cell treatments.
About
Industries
Biotechnology, Therapeutics
Founded
2023
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Shinobi Therapeutics headquartered in United States, North America, operates in the Biotechnology, Therapeutics sector. The company focuses on Biotechnology and has secured $4.3B in funding across 24 round(s). With a team of 11-50 employees, Shinobi Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Shinobi Therapeutics, raised $68.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
2
Lead Investors
0
Total Funding Amount
$178.0M
Details
2
Shinobi Therapeutics has raised a total of $178.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2023 | Early Stage Venture | 51.0M | ||
| 2024 | Early Stage Venture | 68.0M |
Investors
Shinobi Therapeutics is funded by 15 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| AMED | - | FUNDING ROUND - AMED | 59.0M |
| Mitsubishi UFJ Capital | - | FUNDING ROUND - Mitsubishi UFJ Capital | 68.0M |
| Shinobi Therapeutics | - | FUNDING ROUND - Shinobi Therapeutics | 68.0M |
| Yosemite | - | FUNDING ROUND - Yosemite | 68.0M |
Recent Activity
There is no recent news or activity for this profile.